BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 32927790)

  • 1. The Impact of Genetic Polymorphisms in Organic Cation Transporters on Renal Drug Disposition.
    Zazuli Z; Duin NJCB; Jansen K; Vijverberg SJH; Maitland-van der Zee AH; Masereeuw R
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32927790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PPAR-α Deletion Attenuates Cisplatin Nephrotoxicity by Modulating Renal Organic Transporters MATE-1 and OCT-2.
    Freitas-Lima LC; Budu A; Arruda AC; Perilhão MS; Barrera-Chimal J; Araujo RC; Estrela GR
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33049997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin.
    Chang C; Hu Y; Hogan SL; Mercke N; Gomez M; O'Bryant C; Bowles DW; George B; Wen X; Aleksunes LM; Joy MS
    Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28640195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy.
    Nies AT; Koepsell H; Damme K; Schwab M
    Handb Exp Pharmacol; 2011; (201):105-67. PubMed ID: 21103969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events.
    Iwata K; Aizawa K; Kamitsu S; Jingami S; Fukunaga E; Yoshida M; Yoshimura M; Hamada A; Saito H
    Clin Exp Nephrol; 2012 Dec; 16(6):843-51. PubMed ID: 22569819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered pharmacokinetics of cationic drugs caused by down-regulation of renal rat organic cation transporter 2 (Slc22a2) and rat multidrug and toxin extrusion 1 (Slc47a1) in ischemia/reperfusion-induced acute kidney injury.
    Matsuzaki T; Morisaki T; Sugimoto W; Yokoo K; Sato D; Nonoguchi H; Tomita K; Terada T; Inui K; Hamada A; Saito H
    Drug Metab Dispos; 2008 Apr; 36(4):649-54. PubMed ID: 18180268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research progress in the organic cation transporters.
    Shu Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 36(10):913-26. PubMed ID: 22086000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human organic cation transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as disposition pathways for fluoroquinolone antimicrobials.
    Mulgaonkar A; Venitz J; Gründemann D; Sweet DH
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2705-11. PubMed ID: 23545524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic and Epigenetic Regulation of Organic Cation Transporters.
    Kölz C; Schaeffeler E; Schwab M; Nies AT
    Handb Exp Pharmacol; 2021; 266():81-100. PubMed ID: 33674913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of the SLC22A1, SLC22A2, and SLC22A3 genes encoding organic cation transporters with diabetic nephropathy and hypertension.
    Sallinen R; Kaunisto MA; Forsblom C; Thomas M; Fagerudd J; Pettersson-Fernholm K; Groop PH; Wessman M;
    Ann Med; 2010 May; 42(4):296-304. PubMed ID: 20429798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Organic Cation Transporter 2 Overexpression May Confer an Increased Risk of Gentamicin-Induced Nephrotoxicity.
    Gai Z; Visentin M; Hiller C; Krajnc E; Li T; Zhen J; Kullak-Ublick GA
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5573-80. PubMed ID: 27401566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of basolateral organic anion and cation transporters in experimental cadmium nephrotoxicity in rat kidney.
    Ljubojević M; Breljak D; Herak-Kramberger CM; Anzai N; Sabolić I
    Arch Toxicol; 2016 Mar; 90(3):525-41. PubMed ID: 25588984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of organic cation transporters in drug-induced toxicity.
    Ciarimboli G
    Expert Opin Drug Metab Toxicol; 2011 Feb; 7(2):159-74. PubMed ID: 21241199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal tumours in a Tsc1+/- mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin.
    Yang J; Kalogerou M; Gallacher J; Sampson JR; Shen MH
    Eur J Cancer; 2013 Apr; 49(6):1479-90. PubMed ID: 23228442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic variation in organic cation transporters and considerations in drug development.
    Varma MVS
    Expert Opin Drug Metab Toxicol; 2023 Mar; 19(3):149-164. PubMed ID: 37070463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polyspecific organic cation transporters and their biomedical relevance in kidney.
    Koepsell H
    Curr Opin Nephrol Hypertens; 2013 Sep; 22(5):533-8. PubMed ID: 23852330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Organic anion and cation transporter expression and function during embryonic kidney development and in organ culture models.
    Sweet DH; Eraly SA; Vaughn DA; Bush KT; Nigam SK
    Kidney Int; 2006 Mar; 69(5):837-45. PubMed ID: 16518343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences.
    Choi MK; Song IS
    Drug Metab Pharmacokinet; 2008; 23(4):243-53. PubMed ID: 18762711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organic cation transporters OCT1, 2, and 3 mediate high-affinity transport of the mutagenic vital dye ethidium in the kidney proximal tubule.
    Lee WK; Reichold M; Edemir B; Ciarimboli G; Warth R; Koepsell H; Thévenod F
    Am J Physiol Renal Physiol; 2009 Jun; 296(6):F1504-13. PubMed ID: 19357179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal Drug Transporters and Drug Interactions.
    Ivanyuk A; Livio F; Biollaz J; Buclin T
    Clin Pharmacokinet; 2017 Aug; 56(8):825-892. PubMed ID: 28210973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.